Netherlands-based argenx has published positive topline results from its ADAPT SERON trial of its market-leading drug for generalised myasthenia gravis (gMG) Vyvgart (efgartigimod). Significantly, the ...
Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 agonists for diabetes, with new data for Mounjaro on cardiovascular outcomes. The results of the SURPASS-CVOT trial showed ...
In a Forrester article titled Are B2B Buyers Cowards?, researchers debunk the myth that B2B buyers are overly cautious or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback